Janus Henderson Group PLC Buys 257,022 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Janus Henderson Group PLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 7.7% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,588,571 shares of the medical equipment provider's stock after acquiring an additional 257,022 shares during the quarter. Janus Henderson Group PLC owned 5.16% of Lantheus worth $393,844,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC raised its holdings in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 208 shares during the last quarter. Signaturefd LLC increased its position in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 92 shares during the period. Nkcfo LLC bought a new position in Lantheus in the 2nd quarter worth $47,000. UMB Bank n.a. raised its holdings in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus in the 3rd quarter worth about $51,000. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LNTH. Truist Financial reissued a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Redburn Atlantic began coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price on the stock. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. Finally, JMP Securities cut their price objective on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $125.71.

Lantheus Trading Up 0.4 %

LNTH stock traded up $0.33 during midday trading on Wednesday, hitting $88.84. The company's stock had a trading volume of 448,019 shares, compared to its average volume of 1,020,414. The company has a market cap of $6.18 billion, a PE ratio of 14.78 and a beta of 0.45. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The firm's 50-day moving average is $100.06 and its 200-day moving average is $97.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.